Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Phase 3

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Academisch Ziekenhuis Maastricht

Target Recruit Count: 140

Registration Number: NCT00003558

Locations: 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Phase 2

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 241

Registration Number: NCT00045461

Locations: 🇩🇪
Charite University Hospital - Campus Virchow Klinikum, Berlin, Germany
🇩🇪
Universitaets - Kinderklinik - Luebeck, Luebeck, Germany
🇩🇪
Kreiskrankenhaus Trostberg, Trostberg, Germany

and more 4 locations

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Registration Number: NCT00017225

Locations: 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪
Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪
Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany

and more 85 locations

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 75

Registration Number: NCT00025103

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

and more 17 locations

Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 50

Registration Number: NCT00025077

Locations: 🇬🇧
Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom

and more 17 locations

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-25

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT00003111

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 819

Registration Number: NCT00028743

Locations: 🇨🇦
Lions Gate Hospital, North Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 25 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: paclitaxel
Drug: topotecan hydrochloride
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 65

Registration Number: NCT00033696

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

and more 48 locations

Combination Chemotherapy in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Biological: sargramostim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-08-01

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 573

Registration Number: NCT00003093

Locations: 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸
MBCCOP - Hawaii, Honolulu, Hawaii, United States

and more 231 locations

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-08-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 704

Registration Number: NCT00003636

Locations: 🇬🇧
University College of London Hospitals, London, England, United Kingdom
🇨🇦
Doctor H. Bliss Murphy Cancer Centre, St. Johns, Newfoundland and Labrador, Canada
🇦🇹
Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital, Vienna, Austria

and more 62 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy